The present invention includes anhydrous crystalline forms of (2S,4S)-4-fluoro-1-[4-fluoro-.beta.-(4-fluorophenyl)-L-phenylalanyl]-2-py- rrolidinecarbonitrile p-toluenesulfonic acid salt.